Trial Profile
Patterns of usage and patient outcomes associated with Pembrolizumab in a observational study of patients with advanced melanoma covered in electronic health records (EHR) of McKesson Specialty Health.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Feb 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 13 Jun 2017 New trial record
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology